-+ 0.00%
-+ 0.00%
-+ 0.00%

Immix Biopharma Announces Surpassing 50% Enrollment Milestone in NEXICART-2 Clinical Trial for Relapsed/Refractory AL Amyloidosis

Reuters·09/18/2025 17:30:15

Please log in to view news